However, the current study established CDKN2A/B deep deletions as specifically enriched in S/R compared to non-S/R RCC tumors as well as depletion in KDM5C mutations and enrichment in EZH2 amplifications in S/R RCC tumors. This evidence concerns the gene EZH2 and renal cell carcinoma.